FRONTOTEMPORAL DEMENTIA

This early-stage trial tests a gene therapy called PBFT02 in 30 adults with frontotemporal dementia caused by mutations in the GRN or C9ORF72 genes. The therapy delivers a working copy of the GRN gene directly into the brain to help restore a missing protein. The main goals are t…

This study tests an experimental drug called DNL593 in healthy volunteers and people with frontotemporal dementia (FTD), a rare brain disease that causes personality changes and memory loss. The trial aims to check if the drug is safe, how the body processes it, and whether it mi…

This study tests whether metformin, a common diabetes drug, is safe for people with a specific genetic form of ALS (C9orf72). Researchers will also check if it lowers toxic proteins linked to the disease. About 41 participants will take metformin for 24 weeks.

This study tests a new gene therapy (LY3884963) for people with frontotemporal dementia caused by a GRN gene mutation. The therapy aims to increase levels of a key protein called progranulin, which is low in these patients. About 35 adults with mild to moderate symptoms will rece…

This study explores whether playing rhythmic music together can improve social attention and feelings of closeness in people with mild to moderate frontotemporal dementia or Alzheimer's disease, along with their caregivers. About 80 pairs (patient and caregiver) will take part in…

This study tests a new way to match dementia caregivers with each other for emotional support using a computer algorithm. Researchers want to see if matching based on personal preferences leads to better satisfaction and less stress than random matching. About 355 caregivers of p…

This study asks 1000 people with neurological diseases (like Alzheimer's or Parkinson's) and their caregivers to share their experiences using a head device called MemorEM. The goal is to learn how to improve the device's design and make it easier to use in future studies. This i…

This study is creating a simple test to check if people with Alzheimer's or similar conditions can understand and agree to medical decisions. Researchers will work with 100-150 participants to compare the new test with existing methods and look at brain scans and blood markers. T…

This study looks at whether a protein called neurofilament light chain in the blood can help track brain changes in people who have a family history of frontotemporal dementia. About 342 participants will give blood samples every 3 months for 3 years, all from home. The goal is t…

This study looks at people with ALS and similar diseases like frontotemporal dementia and hereditary spastic paraplegia. Researchers want to understand how genes affect the disease and find biological markers (biomarkers) to help develop future treatments. About 708 participants,…

This study aims to see if a remote monitoring platform using wearable sensors can effectively track movement symptoms in people with Progressive Supranuclear Palsy (PSP) and related conditions. About 60 participants will wear a pendant sensor for 12 months to collect data on thei…

This study aims to learn more about ALS and similar neurodegenerative diseases by looking at how a person's genetic makeup relates to their symptoms. Researchers will also search for biomarkers—biological signs that can help track or diagnose these conditions. About 217 adults wi…

This study enrolls people with ALS and related disorders, as well as healthy volunteers, to track biological markers (biomarkers) in urine, blood, and spinal fluid. The goal is to better understand how these markers change over time, which could help design more effective future …